(PDF VERSION HERE)

Day 1: Sunday, May 2

3.00 - 7.15 PM: Registration Open

Technology Session I: 4.00 – 7.00 PM
Session Chair: David Dorris, PhD.

4.00 – 4.30 PM: David Dorris, PhD.
Director, RNA Interference Technologies, Ambion, Austin, TX
Title: Target Validation Experiments of Kinases Using Highly Effective siRNAs

4.30 – 5.00 PM Knut Madden, PhD.
Staff Scientist, Invitrogen Corporation, Carlsbad CA
Title: Lentiviral delivery of inducible RNAi cassettes

5.00 – 5.30 PM Boro Dropulic, PhD.
Founder & CSO, VIRxSYS Corporation, Gaithersburg, MD
Title: Highly efficient delivery of an inhibitory anti-HIV RNA in primary T lymphocytes by a HIV based lentiviral vector

5.30 – 5.45 PM Refreshment Break
Sponsored by novosom AG, Halle, Germany

5.45 – 6.15 PM Dr. Steffen Panzner
Chief Scientific Officer, novosom AG, Halle, Germany
Title: SMARTICLES® – in vitro and in vivo delivery of therapeutic nucleic acids

6.15 – 6.45 PM Lynne Rainen, PhD.
Scientific Director
PreAnalytiX GmbH & BD Preanalytical Systems, Franklin Lakes, NJ
Title: Minimizing preanalytical variability in RNA based clinical studies through integrated collection, stabilization and purification

6.45 – 7.15 PM Imran Ahmad, PhD.
Chief Scientific Officer & Sr. VP, R & D, NeoPharm, Inc. Lake Forest, IL
Title: NeoPhectin-AT™: A Unique Ready to Use In Vivo Delivery System for siRNA

7.15 PM CLOSE of the Session and Opening of the Hall for Exhibit Arrangements

Day 2: Monday, May 3

7:00 A.M: Registration Open

7:30 – 9:00 AM: Continental breakfast:
Sponsored by Atugen AG, Berlin, Germany

Technology Session II: 8.00 – 9.00 AM
Session Chair: William Marshall, PhD.

8.00 – 8.30 AM William Marshall, PhD.
Vice President, R & D, Dharmacon, Lafayette, CO

Title: Recent Enabling Developments in the Application of siRNA Based Gene Silencing

8.30 – 9.00 AM Thomas Grunfeld, MD.
CEO, Interagon AS, Oslo, Norway
Title: Improved identification of optimal siRNAs by deployment of extreme compute capacity technology

9.00 - 9.10 AM Break

9.10 - 9.25AM Chairman’s Welcoming Note
? K. Appasani, PhD., MBA. GeneExpression Systems, Inc.
Recent Scientific and Business hype of RNAi

9. 25 – 9.30 PM Announcement of RNAi Innovator and Micro RNA Discoverer Awards

9.30 – 10.40 AM Session I. Basic Biology of RNAi and MicroRNAs

9.30 – 10.05 AM Keynote Lecture on RNAi By
Craig Mello, PhD.
Professor and Blais University Chair in Molecular Medicine & Assistant Investigator HHMI
University of Massachusetts Medical School, Worcester, MA
Title: RNAi and Development in C. elegans

10.05 – 10.40 AM Keynote Lecture on MicroRNAs By
Gary Ruvkun, PhD.
Professor of Molecular Biology,
Massachusetts General Hospital, Harvard Medical School, Boston
Title: Functional Genomic and Genetic Analysis of RNAi and MicroRNA Pathaways

10.40 – 11.15 AM Refreshment Break (35 min)
Sponsored by Intradigm Corporation, Rockville, MD
Opening of Exhibit Booths

11.15 AM – 12. 40 PM Session II. Design, Synthesis & New Chemistries for
Therapeutic Development
Session Chair: Roberto Weinmann, PhD.
Director of Oncogenomics, Bristol Myers Squibb, Princeton, NJ

11. 20 – 11. 45 AM Aimee Jackson, PhD.
Senior Research Biologist, Rosetta Inpharmatics/Merck
Title: What can expression profiling tell us about siRNAs?

11.45 AM – 12.10 PM Antonin deFougerolles, PhD.
Director of Research, Alnylam Pharmaceuticals, Cambridge, MA
Title: siRNA Therapeutics - The Path to Products

12.10 – 12.35 PM Nassim Usman, PhD.
Senior VP & Chief Operating Officer, Sirna Therapeutics, Inc.
Title: Development of siRNA-Based Therapeutics

12.35 -12.40 RNAi Business Breaking News: One minute pitch by executives to announce their New Business Development/Investment/Acquisition Strategies

12.40 – 2.00 PM Lunch Break (1 hr. 20 min.)
Lunch Sponsored by Benitec Australia Ltd, the Corporate Sponsor

2.00 – 3.40 PM: Session III: Drug and Therapeutic Development
Session Chair: Steven A. Kriegsman, CytRx Corporation

2.00 – 2.25 PM: Mark Tepper, PhD.
Corporate Vice President, CytRx Corporation, Los Angels, CA
Title: Strategy for developing RNAi as a therapeutic

2.25 - 2.50 PM: John Rossi, PhD.
Professor and Chair of Molecular Biology, Beckman Research Institute
Title: Optimizing RNAi in mammalian cells

2.50 - 3.15 PM: Luk Van Parijs, PhD.
Asst. Professor, Massachusetts Institute of Technology, Cambridge, MA
Title: Studying Disease Process Using RNAi

3.15 - 3.40 PM: Mario Stevenson, PhD.
Professor of Molecular Medicine, Univ. of Mass. Medical School
Title: Manipulating HIV by RNAi

3. 40 – 4.40 PM: Refreshment Break (60 min) Poster viewing and Exhibits
Sponsored by genOway, Cedex, France

4.40 – 6.00 PM: Session IV: Gene Delivery
Session Chair: Luk Van Parijs, PhD.
Assistant Professor, Massachusetts Institute of Technology

4.40 – 5.05 PM: Kader Thiam, PhD.
Director of Transgenic Technologies, genOway, France
Title: Essential Requirements for successful Use of RNAi in Transgenic Mice

5.05 – 5.30 PM Mark A. Kay, M.D., Ph.D.
Professor of Pediatrics and Genetics, Stanford Medical School &
Co-Founder of Avocel, Inc. Sunnyvale, CA
Title: In vivo pre-clinical studies for RNA interference directed therapies for human viral hepatitis infection

5.30 – 5.55 PM: Ronald Scheule, PhD.
Director, Genzyme Corporation, Framingham, MA
Title: Small Interfering RNA Transiently Attenuates Liver Expression from Exogenous Genes and Reduces Subsequent Immune Responses to the Transgene Product in Mice

5.55 PM: End of Day I Sessions

6. 00 – 6.30 PM: Poster and Exhibit booth viewing, & Judging Best Poster, Best Product
Company in the RNAi field

6.30 – 7.30 PM: Networking and Cocktail reception
Sponsored by GeneExpression Systems, Inc.

Day 3: Tuesday, May 4

7:00 A.M: Registration Open

7:30 – 9:00 AM: Continental breakfast Sponsored by BDClontech, Palo Alto, CA

Technology Session III: 8.00 – 8.50 AM
Session Chair: Dmitry Samarsky, PhD.

8.00 – 8.25 AM Bradley J. Scherer, PhD.
BD Biosciences Clontech, Palo Alto, CA
Title: Recent Advances in Viral RNAi Delivery

8.25 – 8.50 AM Dmitry Samarsky, PhD.
Director, Invitrogen Corporation, Natick, MA
Title: RNAi in drug discovery

8.50 - 9.00 AM Break

9. 00 - 9. 10AM Awards Presentation
? K. Appasani, PhD., MBA. GeneExpression Systems, Inc.
Best Poster, Outstanding Abstract and Best Reagent Company Award Announcement

9.10 – 12.45 AM: Session V: Target Validation

9.10 – 9.45 AM Keynote Lecture on Target Validation By
Ken C. Reed, PhD.
Director of Research & Technology, Benitec Australia Ltd.
Session Chair: Ken C. Reed, PhD.

9.45 – 10.10 AM: Klaus Giese, Ph.D.
Chief Scientific Officer and VP Research, atugen AG, Germany
Title: Novel siRNA Structures

10.10 – 10.35 AM: Lata Jayaraman, PhD.
Research Investigator, Bristol-Myers Squibb, Princeton, NJ
Title: Validation of Novel Drug Targets using RNAi

10.35 – 11.00 AM Martin Woodle, PhD.
Chief Executive Officer, Intradigm Corporation, Rockville, MD
Title: In Vivo siRNA: Drug Target Validation and Therapeutics

11.00- 11.30 A.M. Break (30 min) Poster viewing and Exhibits
Sponsored by Altana Research Institute, Waltham, MA
Genzyme Corporation, Framingham, MA

11.30 – 12.45 PM: Session V: Target Validation (contd.)

11.30 – 11.55 PM: Ruitang Deng, PhD.
Senior Research Investigator, Global R & D, Pfizer Inc. Groton, CT
Title: RNAi Technology Development and Applications in Drug Discovery

11.55- 12.20 PM: Oliver Steinbach, PhD.
Director, Functional Cloning, ALTANA Research Institute, Waltham, MA
Title: RNAi for Target Identification and Validation in Drug Development

12.20 – 12.45 PM: Judith Lieberman, MD., PhD.
Associate Professor of Pediatrics, Harvard Medical School &
Investigator at Centre for Blood Research, Boston, MA
Title: Silencing the Messenger: Towards In Vivo Delivery

12.45 – 2.00 PM: Lunch Break (1 hr. 15 min) on your own

2.00 – 3.40 PM: Session VI: High throughput Methods & Genome-wide RNAi
Session Chair: Eric Lader, PhD.

2.00- 2.25 PM: Michael Butros, PhD.
Boveri-Group Leader, German Cancer Research Center, Heidelberg, Germany
Title: Genome-wide RNAi to Dissect Cellular Pathways in Drosophila Cells

2.25 – 2.50 PM: Eric Lader, PhD.
Associate Director, Business Development, Qiagen, Germantown, MD
Title: Genome-wide siRNA: Development of an Automated, High Throughput siRNA Design and Synthesis Platform

2.50 - 3.15 PM Kazunari Taira, PhD.
Professor of Chemistry and Biotechnology, University of Tokyo, &
Founder of iGENE Therapeutics, Japan
Title: Lessons from the Small RNA World in the Bio-Medical Revolution

3.15 – 3.40 PM Jen-Tsan Ashley Chi, PhD.
Research Fellow with Prof. Patrick O. Brown, Stanford University Medical School
Title: The monitor of RNA interference activities in mammalian cells

3.40 – 4.00 PM Break (20 min) Poster viewing and Exhibits
Sponsored by Bristol Myers Squibb Company, Princeton, NJ
4.00 PM: Removal of Posters and Exhibit booths

4.00 – 5.00 PM: Session VII. Technology transfer, Investment opportunities and Panel Discussion

4.00 – 4.05 PM: Krishnarao Appasani, PhD., MBA. Moderator
Introduction of the Panel Members

4.00 – 4.05 PM: Irene Abrams
Technology Licensing Officer, Mass. Institute of Technology
Title: Licensing Perspectives on RNAi/siRNA

4.05 – 4.10 PM: Douglas Fambrough Ph.D.
Oxford Bioscience Partners, Boston, MA
Title: Venture Capitalist’s Perspectives on RNAi

4.10 – 4.15 PM: Eileen Smith Ewing Esq.
Partner; Chair, Life Sciences Group
Kirkpatrick & Lockhart LLP, Boston, MA
Title: Legal Perspectives on RNAi
4.15 – 4.55 PM Panel Discussion with experts from:
- Venture Capital Firm
- Technology Transfer Office
- Patent Attorney from a Law firm
- A Professional science writer from a Science/Business Journal*
and selected speakers from this conference.

4.55 – 5.00 PM: CLOSING REMARKS BY THE CHAIRMAN

* Speaker names, titles and order may subject to change.

Font sizes of some of the presentations might be changed during the production of this proceeding. GES is not responsible for such changes.
Materials presented in this book/website should not be reproduced without the permission of GeneExpression Systems, Inc.

© GeneExpression Systems, Inc.